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INTRODUCTION 
Oral controlled release drug delivery systems offer a 
number of advantages over the conventional immediate 
release delivery preparations. These systems are designed 
to deliver the drugs at a controlled and predetermined rate 
thus maintaining their therapeutically effective 
concentration in systemic circulation for prolonged period. 
On the other hand, for certain therapies a pulsatile drug 
release pattern, where the drug is released after well-
defined lag time, exhibits significant advantages. It is well 
documented that most of the body functions display 
circadian rhythms, e.g. heart rate, stroke volume, blood 
pressure, blood flow, body temperature, gastric-pH.
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Moreover, in a number of organs their functions vary with 
the time of the day. It is increasingly recognized that there 
are rhythmic and temporal patterns in the manifestation of 
many disease states. The symptoms for a number of 
diseases, such as bronchial asthma, myocardial infarction, 
angina pectoris, hypertension, rheumatic diseases etc. 
follow a circadian rhythm.
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Circadian rhythms are self-sustaining, endogenous 
oscillations that occur with a periodicity of about 24 
Hours.
3
 Interestingly, the term circadian is derived from 
the Latin circa which means “about” and dies which can be 
defined as “a day”. Normally, circadian rhythms are 
synchronized according to internal biologic clocks related 
to the sleep-wake cycle. Our circadian rhythm is based on 
sleep-activity cycle and is influenced by our genetic 
makeup and thereby affects our body’s function 
throughout day and night (24-hour period). Circadian 
rhythm regulates many body functions in humans like 
metabolism, physiology, behaviour, sleep pattern, hormone 
production
4
 as many conditions show circadian pattern, 
advantage could be taken by timing and adjusting the 
administration of drugs according to the circadian rhythm 
of the disease. 
Oral pulsatile administration could be useful for the 
treatment of certain diseases, such as asthma, gastric ulcer, 
hypertension, ischemic heart disease, arthritis, etc., which 
exhibit circadian rhythms. A pulsatile release profile is 
characterized by a lag time followed by rapid and complete 
drug release. Most pulsatile systems are reservoir systems 
and usually covered with a barrier. This barrier can be 
dissolved, eroded or removed at a predetermined period of 
time after which the drug is dissolved and rapidly released. 
Meloxicam is an nonsteroidal anti-inflammatory drug 
(NSAID) with analgesic and antipyretic properties. 
Prostaglandins are substances that contribute to 
inflammation of joints. Meloxicam inhibits prostaglandin 
synthetase (cylooxygenase 1 and 2) and leads to a decrease 
of the synthesis of prostaglandins, therefore, inflammation 
is reduced.
5
 Pulsatile drug delivery system is a controlled 
drug delivery system where drug is released after a pre-
programmed lag time. Various approaches have been used 
to design a pulsatile release formulation, erodible devices 
provided with hydrophilic polymer coating are widely used 
and such a system when exposed to dissolution medium 
undergo swelling, dissolution and/or erosion. Lag time in 
such a system can be controlled by using various 
hydrophilic polymers such as HPMC, polyethylene oxide, 
sodium alginate, sodium CMC. The concentration and 
viscosity of these polymers play a significant role in 
controlling the lag time and release pattern.
6
       
A Capsular system in which the body part coated with 
impermeable polymer and hydrophilic matrix plug sealing 
the drug formulation is used to prepare pulsatile drug 
delivery system. Upon contact with aqueous fluids a rapid 
dissolution would occur and plug undergoes a gradual 
swelling and finally expluded from the body thus allowing 
the drug to release. The lag time in such formulation 
controlled by the time needed for the plug removal and its 
duration depends on the physical, chemical nature, size 
and position of the plug.
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ABSTRACT 
The objective of this work is to formulate a pulsatile drug delivery system using Meloxicam drug. The drug delivery system 
was designed to deliver the drug in such a way that it could be most useful to the patient of rheumatoid arthritis. A core in cup 
(three component tablet) is prepared where in core tablet, an impermeable material surrounding the tablet except the top and 
soluble hydrophilic polymer layer at the top is designed. The core tablet contains Meloxicam, ethyl cellulose is used as 
impermeable membrane and polyethylene oxide used as soluble hydrophilic polymer layer. The release profile of press coated 
tablet exhibited a lag time followed by burst release, in which outer shell ruptured into two halves. The effect of the core, the 
polymer characteristics and quantity at the top cover layer, on the lag time and drug release was investigated. The prepared 
tablets were evaluated for uniformity of weight, hardness, friability, wetting time, in-vitro disintegration time, stability study 
and drug release study. Fourier transform infrared spectroscopy study showed compatibility between Meloxicam and coating 
material. 
Keywords: Pulsatile Release Tablet, Press-coated tablet, Rheumatoid arthritis. 
 
 
Ratnaparkhi et al                            Journal of Drug Delivery & Therapeutics; 2013, 3(4), 229-236 230 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
The aim of the present work is to develop a simple one 
pulse drug delivery system based on dry coated tablet 
preparation. The system consist of a core tablet containing 
the drug, an impermeable outer shell and top cover layer 
barrier that dissolves at predetermined time. Ethyl 
cellulose is used as insoluble material and a Polyethylene 
oxide 301, Polyethylene oxide 303 and Hydroxy propyl 
cellulose used as hydrophilic top layer. The drug is 
released after removal of top layer of hydrophilic polymers 
and the lag time being adjusted by properties of the 
material in top cover, Meloxicam is used as model drug. 
MATERIALS AND METHOD 
Materials:                                                                                                     
Meloxicam were obtained from Jai Radhe Sales 
Ahmedabad, India. Ethyl cellulose, L-Hydroxy propyl 
cellulose, Polyethylene oxides were gifted from Colorcon 
Asia Pvt.Ltd. Micro Crystalline Cellulose Croscarmellose 
Sodium, Magnesium Stearate, Potassium Dihydrogn 
Phosphate, Disodium Hydrogen Phosphate was obtained 
from Loba Cheim Pvt. Ltd.  All the other chemicals and 
reagents were either analytical or pharmaceutical grades. 
Tablet Manufacturing Method                                                                     
Formulation of Core Tablet by Direct Compression 
Method:  
The rapid release core tablets were prepared using a 
compression machines (Labpress) with suitable flat 
punches. The core was made of the suitable mixture of 
powder blends of Meloxicam, Microcrystalline Cellulose 
(MCC, Avicel PH-102), Croscarmellose Sodium (Ac-Di-
Sol), Sodium starch glycolate and Magnesium stearate was 
used in different batches. All above ingredients were dry 
blended for 20 minutes followed by addition of 
Magnesium Stearate. The mixture was then further 
blended for 10 minutes. The 80 mg of the resultant mixture 
then directly compressed at a pressure of 1 ton for 1minute 
using 6 mm punch and die. Shown in Table no.1 
      Table No1:- Composition of Core Tablet 
 
Formulation of Press Coated Tablet by Direct Mixing: 
In this method the coating material mixtures were 
previously passed through the sieve no. 44 and half 
quantity of the powder mixture was used for the upper and 
lower shell. The press coating of tablets was performed 
using a rotary tablet machine.  A half amount of the 
powder was filled into the die to make a powder bed, in the 
center of which core tablet was placed manually. Then, the 
remaining half of the coating material filled in the die, and 
the contents were compressed under a sufficient 
compression force, using a suitable punch. Shown in Table 
no. 2 
 
Table 2: Composition of Press Coated Tablet by Direct Mixing 
 
Formulation of Press Coated Tablets by Impermeable 
Cup Shaped Method:                        
 An impermeable coating cup consisting of ethyl cellulose 
was applied in the bottom and around   the core tablet. The 
ethyl cellulose powder was filled into a die of 10mm 
diameter and then was gently compacted to make a powder 
bed with a flat surface. The core tablet was in turn 
carefully placed in centre of powder bed next the die was 
filled with the reminder of the coating powder so that 
Formulation Code Drug 
(mg) 
Microcrystalline 
Cellulose (mg) 
Cross Carmellose 
Sodium (mg) 
Magnesium 
Stearate (mg) 
Total (mg) 
A1 15 62 1 2 80 
A2 15 61 2 2 80 
A3 15 59 4 2 80 
A4 15 57 6 2 80 
A5 15 55 8 2 80 
Formulation 
Code 
Core Tablet 
Wt.(mg) 
Coating Material Coating 
Material Upper 
Layer (mg) 
Coating Material 
Bottom  Layer 
(mg) 
EC (mg) L-HPC 
(mg) 
Polyox 
301 (mg) 
Polyox 
303 (mg) 
FA1 80 150 150 - - 150 150 
FA2 80 200 100 - - 150 150 
FA3 80 225 75 - - 150 150 
FA4 80 250 50 - - 150 150 
FB1 80 250 - 50 - 150 150 
FB2 80 260 - 40 - 150 150 
FB3 80 270 - 30 - 150 150 
FB4 80 280 - 20 - 150 150 
FC1 80 250 - - 50 150 150 
FC2 80 260 - - 40 150 150 
FC3 80 270 - - 30 150 150 
FC4 80 280 - - 20 150 150 
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surrounding surfaces of the core tablet was fully covered. 
On the top hydrophilic polymer was added and last bed 
was compressed to produce the desired core-in-cup 
system. Shown in Table No. 3 
Table 3: Composition of Press Coated Tablet by Cup shaped Method 
Formulation 
Code 
Core Tablet 
Wt.(mg) 
Coating Material in Cup Shape Coating Material in Upper Layer 
EC(mg) L-HPC 
(mg) 
Polyox 
301 (mg) 
Poloyx 
303 (mg) 
FD1 80 100 75 - - 
FD2 80 100 100 - - 
FD3 80 100 125 - - 
FD4 80 100 150 - - 
FE1 80 100 - 75 - 
FE2 80 100 - 100 - 
FE3 80 100 - 125 - 
FE4 80 100 - 150 - 
FF1 80 100 - - 75 
FF2 80 100 - - 100 
FF3 80 100 - - 125 
FF4 80 100 - - 150 
 
Evaluation of core and press – coated tablet 
Preformulation Study: 
Bulk density, tapped density, hausner’s ratio, carr’s index 
and angle of repose was perform for polymeric blends.
8 
Characterization of Core and Press Coated Tablets 
Thickness: 
Thickness of tablets was determined using Vernier caliper. 
Five tablets from batch were used, and average values 
were calculated. 
Average Weight: 
To determine average weight, each tablet from formulation 
was weighed using an electronic balance. 
Hardness: 
The hardness was tested using Monsanto tester. The force 
is measured in kilograms/cm
2
. 
Uniformity of Content: 
The tablet from each batch was powdered individually and 
a quantity equivalent to 80mg of Meloxicam was 
accurately weighed and dissolved in a suitable volume of 
6.8 pH phosphate buffer. After making suitable dilutions 
the final solution was analyzed spectrophotometrically at 
λmax of drug. 
 Friability: 
For each formulation, the friability of 6 tablets was 
determined using the Roche friabilator (Lab Hosp.).
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Twenty tablets were initially weighed (Initial Wt) and 
transferred into friabilator. The Friabilator was operated at 
25 rpm for 4 minutes or run up to 100 revolutions. The 
tablets were weighed again (Final Wt). The % friability 
was then calculated by, 
 
Disintegration Test: 
Six core tablets were selected randomly from each batch 
for the disintegration test. Disintegration test was 
performed in simulated colonic fluid (SCF) using Veego 
Disintegration Tester (microprocessor based), and 
Disintegration time (DT) was measured.
10 
Drug Excipient Interaction: 
Compatibility of the Drug with the excipients is 
determined by subjecting the physical mixture of the drug 
and the polymers of the main formulation to infrared 
absorption spectral analysis (FTIR). Any changes in 
chemical composition of the drug after combining it with 
the polymers were investigated with I.R. spectral analysis. 
In vitro Drug Release Study of Press Coated Tablets: 
Dissolution studies were carried out using USP Apparatus 
II (Veego) at a rotation speed of 50 rpm and at 37 ± 0.5°C 
using 900 mL of 0.1 N HCl for two hours, followed by 900 
mL of pH 6.8 phosphate buffer as the dissolution media. 
At appropriate time intervals, 1ml dissolution samples 
were withdrawn and replaced with 1ml of fresh solution 
maintained at the same temperature. Samples were 
analyzed by ultraviolet visible spectrophotometry 
(Shimadzu UV-1800, Japan). The amount of Meloxicam 
dissolved in the dissolution media was then determined 
from the calibration curve and the cumulative percentage 
of Meloxicam released was calculated.
 11
 
Stability Study:  
After determining the drug content, the optimized batches 
of tablet were monitored up to 1 month at accelerated 
stability conditions of temperature and relative humidity 
(40°
 
± 2°C /75%± 5%RH). Samples were withdrawn after 
one month and characterized for Appearance, Weight, 
Thickness, Hardness, drug content, drug release. The 
choice of appropriate storage condition during accelerated 
stability study is necessary to predict the long term 
stability of Meloxicam tablet. The humidity during storage 
is also extremely important, considering the hygroscopic 
nature of hydrophilic polymers
.12 
RESULT AND DISCUSSION
 
Preformulation Study:  
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The powder blend indicated good flowability with the 
angle of repose values ranging from 26° to 36° according 
to fixed funnel method. The results of bulk density, tapped 
density and compressibility index are shown in Table No. 
4. The result of compressibility index was between 
16.12±1.36 to 20.78±2.13, which indicates good to fair 
flow properties. 
 
Table 4: Precompression Parameters of Core Tablets 
 
Post Compression Characterization of Core Tablet: 
Post compression characterization of core tablet are performed and all result are found to be within pharmacopeial limit 
which is shown in Table No. 5 
Table 5: Post Compression Characterization of Core Tablet 
 
Post Compression Characterization of Press Coated Tablet: 
Post compression Characterization of Press Coated Tablet are performed and all result are found to be within 
pharmacopeial limit which is shown in Table No. 6 
Table 6: Post Compression Characterization of Press Coated Tablet 
Formulation Weight Variation 
(mg) 
Diameter 
(mm) 
Thickness 
(mm) 
Hardness 
(kg/cm
2
) 
Friability 
(%) 
Drug 
Content (%) 
FA1 379.34±0.26 10.02±0.003 6.5±0.12 9.23±1.30 0.56 99.34 
FA2 379.44±0.72 10.01±0.016 6.4±0.13 9.54±1.41 0.54 98.27 
FA3 379.93±0.47 10.00±0.002 6.5±0.09 9.40±2.42 0.63 99.23 
FA4 379.56±0.07 10.00±0.023 6.6±0.21 8.92±1.32 0.57 97.85 
FB1 379.83±0.35 10.03±0.011 6.5±0.23 9.44±0.13 0.53 98.66 
FB2 380.21 ±036 10.00±0.045 6.4±0.15 10.72±1.11 0.72 96.49 
FB3 379.24±0.13 10.01±0.005 6.5±0.12 8.86±1.76 0.56 97.64 
FB4 379.50±0.64 10.00±0.003 6.5±0.12 9.32±1.81 0.52 99.83 
FC1 380.12±0.75 10.02±0.009 6.5±0.13 8.22±0.45 0.51 97.23 
FC2 379.32 ±035 10.02±0.017 6.4±0.23 9.64±1.32 0.73 99.68 
FC3 379.18±0.08 10.03±0.002 6.6±0.14 9.75±2.75 0.64 99.32 
FC4 379.40±0.17 10.01±0.035 6.5±0.11 9.63±1.44 0.63 97.69 
FD1 254.24±0.91 10.02±0.015 6.5±0.12 10.11±0.13 0.54 98.56 
FD2 279.56±0.63 10.00±0.005 6.6±0.13 9.53±1.27 0.61 99.11 
FD3 305.04±0.82 10.00±0.023 6.4±0.11 9.32±2.14 0.56 99.45 
FD4 329.44±0.43 10.01±0.007 6.6±0.14 9.06±1.13 0.67 97.48 
FE1 254.32±0.34 10.01±0.034 6.4±0.12 8.52±1.41 0.57 96.89 
FE2 279.78±0.16 10.00±0.012 6.5±0.13 9.12±1.09 0.64 98.34 
FE3 304.43±0.12 10.00±0.113 6.5±0.07 8.89±2.41 0.55 97.84 
FE4 329.70±0.27 10.00±0.005 6.5±0.23 9.76±1.14 0.73 98.92 
FF1 254.27±0.72 10.03±0.012 6.6±0.12 9.64±1.33 0.68 99.51 
FF2 279.92±0.68 10.02±0.003 6.5±0.12 10.04±1.25 0.66 97.39 
FF3 304.33±0.32 10.02±0.112 6.4±0.14 9.33±1.28 0.55 99.21 
FF4 329.58±0.21 10.00±0.005 6.5±0.13 9.78±1.45 0.54 99.23 
Formulation Bulk Density  
(gm/cm
3
) 
Tapped Density 
(gm/cm
3
) 
Hausners Ratio Compressibility 
Index 
Angle of 
Repose (°) 
A1 0.509 ±0.008 0.622 ±0.003 1.22 ±0.02 18.16 ±1.34 26.07 ±0.67 
A2 0.482 ±0.017 0.588 ±0.011 1.21 ±0.01 18.02 ±2.45 32.41 ±0.92 
A3 0.484 ±0.004 0.611 ±0.023 1.26 ±0.03 20.78 ±2.13 36.98 ±0.43 
A4 0.479 ±0.006 0.603 ±0.013 1.25 ±0.04 20.56 ±1.22 28.53 ±1.23 
A5 0.494 ±0.013 0.589 ±0.006 1.19 ±0.07 16.12 ±1.36 33.16 ±0.11 
Formulation Weight Variation 
(mg) 
Diameter 
(mm) 
Thickness 
(mm) 
Hardness 
(kg/cm
2
) 
Friability 
(%) 
Drug Content 
(%) 
A1 79.58 ±0.35 6.02 ±0.007 2.34±0.005 4.5 ±0.50 0.355 99.56 
A2 79.68 ±036 6.02 ±0.011 2.36±0.016 4.33 ±0.03 0.361 98.80 
A3 79.47 ±0.31 6.01 ±0.015 2.39±0.014 4.00 ±0.00 0.328 98.33 
A4 79.70 ±0.31 6.01 ±0.011 2.40±0.008 4.0 0±0.50 0.348 98.26 
A5 79.61 ±0.39 6.02 ±0.008 2.42±0.008 3.83± 0.23 0.308 98.93 
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Disintegration Test: 
The core tablets were found to have disintegration time in 
following order A1 < A2 < A3  < A4 < A5 Thus, it was 
found that formulation A5 shows least disintegration time 
of about 76 seconds. Tablets A5 It contains Cross 
Carmellose Sodium in concentration of 8 % hence it was 
selected for further study. All data related to disintegration 
are shown Figure No. 1 
Drug Excipient Interaction: 
FT-IR spectra of Meloxicam (A), Physical mixture 
(Meloxicam+HPC) (B), Meloxicam+Polyox 301(C), 
Meloxicam+Polyox 303(D), Meloxicam+Ethyl Cellulose 
(E), Optimised formulation (F) was shown in Figure No. 2. 
The characteristic absorption peaks of Meloxicam was 
found at 3290 and 1622 cm-1 (N-H stretching), 1552 cm-1 
(C-O stretching), 1163 (S=O stretching) and 1640 cm-1 
(C=N stretching). The spectra revealed no difference in 
positions of the absorption bands, especially with respect 
to OH, NH hence providing the evidence for the absence 
of hydrogen bonding interaction in between polymers and 
Meloxicam. As shown in Figure No. 2 
 
Figure 1: Disintegration time of Core tablets 
 
 
Figure 2: IR spectrum of Meloxicam (A), Meloxicam+HPC (B), Meloxicam+Polyox 301(C), Meloxicam+Polyox 303(D), 
Meloxicam+Ethyl cellulose (E), Optimised formulation (F). 
In Vitro Drug Release Study of Core Tablets: 
The core tablet formulation (A5) containing highest 
amount of Cross Carmellose Sodium showed fast 
disintegration. Shown in Figure No.3 
 
Figure 3: Dissolution profile of core tablet (A1-A5) 
In Vitro Drug Release Study of Press – Coated Tablets: 
In formulation FA1-FA4, FB1-FB4, FC1-FC4 it showed 
that lag time decreases with increasing concentration of 
hydrophilic polymer L-HPC, Polyox 301, Polyox 303. 
Dissolution media get penetrate into coating layer slowly 
and it solubilises L-HPC.  In contact with dissolution 
media Polyox 301 erodes easily so the ethyl cellulose gets 
free from mixture and the core tablet get exposed to 
dissolution media. In contact with dissolution media 
Polyox303 get swelled and due to pressure developed it 
distract ethyl cellulose.  Hence drug diffuses rather than 
bursting of tablet. Batch FA4, FB4, FC4 showed highest 
lag time because it contains high concentration of ethyl 
cellulose and low concentration of L-HPC, Polyox 301, 
Polyox 303. All data are shown in Figure No. 4, 5 and 6. 
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Figure 4: Dissolution profile of Batch FA1-FA4 
 
Figure 5: Dissolution profile of Batch FB1-FB4 
 
Figure 6: Dissolution profile of Batch FC1-FC4 
In contacts with dissolution media L-HPC, Polyox 301, 
Polyox 303 gets eroded slowly. This cause’s dissolution 
media to enter into core tablet resulting in bursting of 
tablet due to pressure develop by superdisintegrant. It 
showed that lag time increases with increasing 
concentration L-HPC, Polyox 301, Polyox 303. Hence 
we can said that lag time is directly proportional to the 
thickness of top layer. All data are shown in Figure No. 
7, 8 and 9. 
 
Figure 7: Dissolution profile of Batch FD1-FD4 
 
Figure 8: Dissolution profile of Batch FE1-FE4 
 
Figure 9: Dissolution profile of Batch FF1-FF4 
After observation it was found that Batch FA4 showed 
sustain type of drug release which is not requiring in 
Pulsatile tablet. This shows that drug release through 
diffusion mechanism as tablet not give essential lag time. 
Batch FB4 and FC4 follows lag time of 3 Hr. but fail to 
give rapid release after that. Hence direct mixing may be 
unsatisfactory method for tested polymer combinations. 
As shown in Figure No.10 
 
Figure 10: Dissolution profile of comparison between 
FA4, FB4, and FC4 
In Batch FD4 ethyl cellulose as impermeable cup and L-
HPC as top layer. It showed bursting effect at 5 hr. But 
batch FE4 and FF4 showed bursting effect at 6 Hrs. 
Batch FE4 contain hydrophilic polymer Polyox 301. 
Polyox 301 is low molecular weight and erodible nature. 
Due to it gets eroded slowly in contacts with dissolution 
media and after lag period of time upper Polyox 301 gets 
removed completely and released drug. Batch FF4 
showed slow release because it contain high molecular 
weight polymer polyox 303 which gets swelled in 
contacts with dissolution media and releases drug after 
lag period of time 6 Hrs. Shown in Figure No.11 
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Figure 11: Dissolution profile of comparison between 
D4, E4, and F4 
It was found that direct mixing methods may permeate 
dissolution media from all sides of tablets because of 
presence of hydrophilic polymer it diffuses drug from all 
sides but in impermeable cup shaped method dissolution 
media do not enter from all sides because presence of 
hydrophobic polymer it can enter into only one side that 
is top layer which is hydrophilic. This gets eroded slowly 
and exposes tablet. Hence in impermeable method 
thickness of top layer is directly proportional to lag time 
of tablet. Shown in Figure No.12 
 
Figure 12: Dissolution profile of Comparison between 
all best batches from direct mixing and impermeable cup 
shaped method 
Stability study: 
The stability study of the FF4 batch in which the tablets 
were monitored. There was little bit but no large 
difference was observed in the evaluation of the FF4 
batch. The dissolution study of the optimized batch at 
zero month and one month show no changes in drug 
release profile both the dissolution study show the 
typical pulsatile profile.  All data of Stability study 
Shown in Table No.7 and Figure No 13 
Table 7: Stability Study 
Parameter At Temp. 40
0
± 20C RH 75% ± 5% 
Appreance Off white Off white 
Drug Content (%) 99.23 ± 0.51 97.56 ± 0.69 
Drug Release after Lag time. (%) 87.16 85.93 
 
 
Figure 13: % drug release before and after stability Study 
CONCLUSION 
Results of present work demonstrated that combination of 
both hydrophilic and hydrophobic polymers by 
impermeable cup shaped method could be successfully 
employed for formulating pulsatile release tablets of 
Meloxicam. The FF4 formulation combination of Ethyl 
Cellulose (bottom cup) and Polyox 303 (top layer) was 
capable of extending the drug release after 6 hours. 
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